REFERENCES
- Vernardet S, Bossaert S, Livrozet A, Pont E, Charpiat B. Pharmaceutical analysis and validation of hospital prescriptions: A five-year study. Presse Med 2005; 34(14)990–996
- Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41
- K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 2002; 39: S1–S246
- Baraldi A, Ballestri M, Rapana R, et al. Acute renal failure of medical type in an elderly population. Nephrol Dial Transplant 1998; 13(Suppl. 7)S25–S29
- Dickerson LM, Mainous AG, III, Carek PJ. The pharmacist's role in promoting optimal antimicrobial use. Pharmacotherapy 2000; 20: 711–723
- Cunningham G, Dodd T, Grant DJ, McMurdo M, Richards M. Drug-related problems in elderly patients admitted to Tayside hospitals: Methods for prevention and subsequent reassessment. Age and Aging 1997; 26: 375–382
- Chow KM, Szeto CC, Hui AC, Li PK. Mechanisms of antibiotic neurotoxicity in renal failure. Int J Antimicrob Agents 2004; 23(3)213–217
- Kenny GNC. Potential renal, hematological and allergic adverse effects associated with nonsteroidal anti-inflammatory drugs. Drugs 1992; 5: 31–37
- Bassilios N, Launay-Vacher V, Deray G. GPR Antibactériens1st. Meditions International, Paris 2002
- Nauta EH, Mattie H, Goslings WR. Pharmacokinetics of cloxacillin in patients on chronic intermittent hemodialysis and in healthy subjects. Chemotherapy 1973; 19(5)261–271
- Bulger RJ, Lindholm DD, Murray JS, Kirby WM. Effect of uremia on methicillin and oxacillin blood levels. Excretion and inactivation in renal failure and hemodialysis. JAMA 1964; 187(5)319–322
- Fillastre JP, Leroy A, Moulin B, Dhib M, Borsa-Lebas F, Humbert G. Pharmacokinetics of quinolones in renal insufficiency. Antimicrob Chemother 1990; 26(Suppl. B)51–60
- Patel IH, Sugihara JG, Weinfeld RE, Wong EG, Siemsen AW, Berman SJ. Ceftriaxone pharmacokinetics in patients with various degrees of renal impairment. Antimicrob Agents Chemother 1984; 25(4)438–442
- Turnidge J. Fusidic acid pharmacology, pharmacokinetics and pharmacodynamics. Int J Antimicrob Agents 1999; 12(Suppl. 2)S23–S34
- Halstenson CE, Opsahl JA, Schwenk MH, et al. Disposition of roxithromycin in patients with normal and severely impaired renal function. Antimicrob Agents Chemother 1990; 34(3)385–389
- Arancibia A, Drouguett MT, Fuentes G, et al. Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function. Int J Clin Pharmacol Ther Toxicol 1982; 20(10)447–453
- Peddie B, Dann E, Bailey RR. The effect of impairment of renal function and dialysis on the serum level and urine levels of clindamycin. Aust N Z J Med 1975; 5(3)198–202
- Yeske H, Bradley JM. Dosage guidelines for cotrimoxazole in renal impairment. The Canadian Journal of Hospital Pharmacy 1987; 40(1)38–39
- Bassilios N, Vantelon C, Baumelou A, Deray G. Continuous rifampicin administration inducing acute renal failure. Nephrol Dial Transplant 2001; 16(1)190–191
- Borghetti A, Di Perna A, Novarini A, Bruschi G, Montanari A. Rifampicin kinetics in patients with kidney disease. Giornale di Clinica Medica 1970; 51(11)857–876
- Lam YW, Kapusnik-Uner JE, Sachdeva M, Hackbarth C, Gambertoglio JG, Sande MA. The pharmacokinetics of teicoplanin in varying degrees of renal function. Clin Pharmacol Ther 1990; 47: 655–661
- Livornese LL, Jr, Slavin D, Gilbert B, et al. Use of antibacterial agents in renal failure. Infect. Dis Clin North Am 2004; 18(3)551–579
- Blix HS, Viktil KK, Reikvam A, et al. The majority of hospitalized patients have drug-related problems: results from a prospective study in general hospitals. Eur J Clin Pharmacol 2004; 60(9)651–658
- Fredman B, Zohar E, Golan E, Tillinger M, Bernheim J, Jedeikin R. Diclofenac does not decrease renal blood flow or glomerular filtration in elderly patients undergoing orthopedic surgery. Anesth Analg 1999; 88: 149–154